Oral Cannabidiol, PTL101, Meets Goals of Phase 1 Study as Possible Spasticity Treatment
Results of a Phase 1 study finds that PTL101, an oral cannabidiol, is a safe and effectively delivered potential treatment for MS-related spasticity.
1 Comment